These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 14967552)

  • 41. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.
    Goodman WK; Kozak MJ; Liebowitz M; White KL
    Int Clin Psychopharmacol; 1996 Mar; 11(1):21-9. PubMed ID: 8732310
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bipolar co-morbidity in pediatric obsessive-compulsive disorder: clinical and treatment implications.
    Masi G; Perugi G; Millepiedi S; Toni C; Mucci M; Pfanner C; Berloffa S; Pari C; Akiskal HS
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):475-86. PubMed ID: 17822342
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder.
    Dell'Osso B; Allen A; Hollander E
    Expert Opin Pharmacother; 2005 Dec; 6(15):2727-40. PubMed ID: 16316311
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overvalued ideation in adolescents with obsessive-compulsive disorder.
    Borda T; Neziroglu F; Taboas W; McKay D; Frenkiel L
    Psychiatry Res; 2017 Sep; 255():66-71. PubMed ID: 28528243
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma prolactin response to d-fenfluramine in obsessive-compulsive patients before and after fluvoxamine treatment.
    Monteleone P; Catapano F; Bortolotti F; Maj M
    Biol Psychiatry; 1997 Aug; 42(3):175-80. PubMed ID: 9232209
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study.
    Poyurovsky M; Isakov V; Hromnikov S; Modai I; Rauchberger B; Schneidman M; Weizman A
    Int Clin Psychopharmacol; 1999 Mar; 14(2):95-100. PubMed ID: 10220124
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
    Piccinelli M; Pini S; Bellantuono C; Wilkinson G
    Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial.
    Shalbafan M; Malekpour F; Tadayon Najafabadi B; Ghamari K; Dastgheib SA; Mowla A; Shirazi E; Eftekhar Ardebili M; Ghazizadeh-Hashemi M; Akhondzadeh S
    J Psychopharmacol; 2019 Nov; 33(11):1407-1414. PubMed ID: 31575326
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early Improvement as a Predictor of Treatment Response in Patients With Obsessive-Compulsive Disorder: A 12-Week Randomized Trial of Sertraline and Fluvoxamine.
    Brar J; Sidana A; Chauhan N; Bajaj MK
    Prim Care Companion CNS Disord; 2022 Mar; 24(2):. PubMed ID: 35364630
    [No Abstract]   [Full Text] [Related]  

  • 50. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients.
    Marazziti D; Golia F; Consoli G; Presta S; Pfanner C; Carlini M; Mungai F; Catena Dell'osso M
    CNS Spectr; 2008 Nov; 13(11):971-6. PubMed ID: 19037176
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.
    Koran LM; McElroy SL; Davidson JR; Rasmussen SA; Hollander E; Jenike MA
    J Clin Psychopharmacol; 1996 Apr; 16(2):121-9. PubMed ID: 8690827
    [TBL] [Abstract][Full Text] [Related]  

  • 52. No effect of adding brief dynamic therapy to pharmacotherapy in the treatment of obsessive-compulsive disorder with concurrent major depression.
    Maina G; Rosso G; Rigardetto S; Chiadò Piat S; Bogetto F
    Psychother Psychosom; 2010; 79(5):295-302. PubMed ID: 20616624
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical picture of obsessive-compulsive disorder with poor insight: a regression model.
    Bellino S; Patria L; Ziero S; Bogetto F
    Psychiatry Res; 2005 Sep; 136(2-3):223-31. PubMed ID: 16125785
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Longitudinal assessment of symptom and subtype categories in obsessive-compulsive disorder.
    Besiroglu L; Uguz F; Ozbebit O; Guler O; Cilli AS; Askin R
    Depress Anxiety; 2007; 24(7):461-6. PubMed ID: 17131352
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Do soft signs predict treatment outcome in obsessive-compulsive disorder?
    Thienemann M; Koran LM
    J Neuropsychiatry Clin Neurosci; 1995; 7(2):218-22. PubMed ID: 7626966
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.
    Pallanti S; Quercioli L; Koran LM
    J Clin Psychiatry; 2002 Sep; 63(9):796-801. PubMed ID: 12363120
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum cholesterol in patients with obsessive compulsive disorder during treatment with behavior therapy and SSRI or placebo.
    Peter H; Tabrizian S; Hand I
    Int J Psychiatry Med; 2000; 30(1):27-39. PubMed ID: 10900559
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictors associated with improved cognitive-behavioral therapy outcome in pediatric obsessive-compulsive disorder.
    Torp NC; Dahl K; Skarphedinsson G; Compton S; Thomsen PH; Weidle B; Hybel K; Valderhaug R; Melin K; Nissen JB; Ivarsson T
    J Am Acad Child Adolesc Psychiatry; 2015 Mar; 54(3):200-207.e1. PubMed ID: 25721185
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.
    Milanfranchi A; Ravagli S; Lensi P; Marazziti D; Cassano GB
    Int Clin Psychopharmacol; 1997 May; 12(3):131-6. PubMed ID: 9248868
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.
    Berlin HA; Koran LM; Jenike MA; Shapira NA; Chaplin W; Pallanti S; Hollander E
    J Clin Psychiatry; 2011 May; 72(5):716-21. PubMed ID: 20816027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.